• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
COVID-19 Management

AstraZeneca-Pfizer Heterologous COVID-19 Vaccine Administration: Is Immunogenicity Improved?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Hillus et al. (The Lancet Respiratory Medicine, 2021) assessed the reactogenicity and immunogenicity of heterologous administration of the AstraZeneca and Pfizer vaccines, compared with homologous immunization

METHODS:

  • Interim analysis of prospective observational cohort study data
  • Participants
    • Healthcare workers in Berlin
    • Enrolled between Dec 2020 and Jun 2021
  • Exposures
    • Homologous (Hom) AstraZeneca vaccination, with a 10-to-12-week interval
    • Homologous (Hom) Pfizer vaccination, with a 3-week vaccine interval
    • Heterologous (Het) AstraZeneca-Pfizer vaccination, with a 10-to-12-week interval
  • Study design
    • Reactogenicity was examined after the first and second dose via electronic questionnaires on days 1, 3, 5, and 7 following immunization
    • Immunogenicity was measured by
      • The presence of SARS-CoV-2-specific antibodies (full spike-IgG, S1-IgG, and RBD-IgG)
      • An RBD–ACE2 binding inhibition assay (virus neutralization test)
      • A pseudovirus neutralization assay against two variants of concerns (alpha [B.1.1.7] and beta [B.1.351])
      • Anti-S1-IgG avidity
    • T-cell reactivity was measured by IFN-γ release assay

RESULTS:

  • Homologous Pfizer: 174 | Homologous AstraZeneca: 38 | Heterologous: 104
  • Participants experiencing systemic symptoms following the second dose
    • Hom Pfizer: 65% (95% CI, 57.1 to 71.8)
    • Hom AstraZeneca: 39% (95% CI, 24.8 to 55.1)
    • Het: 49% (95% CI, 39.6 to 58.5)
  • Median anti-RBD IgG levels 3 weeks after second dose
    • Hom Pfizer: 5.4 signal to cutoff ratio (S/co) (IQR 4.8 to 5.9)
    • Hom AstraZeneca: 4.9 S/co (IQR 4.3 to 5.6)
    • Het: 5.6 S/co (IQR 5.1 to 6.1)
  • Geometric mean of 50% inhibitory dose against alpha and beta variants were highest in participants with the heterologous vaccine regimen, compared to both other vaccine regimens (P<0.0001)
    • Heterologous
      • Against alpha: 956.6 (95% CI, 835.6 to 1095)
      • Against beta: 417.1 (95% CI, 349.3 to 498.2)
    • Homologous Pfizer
      • Against alpha: 369.2 (95% CI, 310.7 to 438.6)
      • Against beta: 72.4 (95% CI, 60.5 to 86.5)
    • Homologous AstraZeneca:
      • Against alpha: 212.5 (95% CI, 131.2 to 344.4)
      • Against beta: 48.5 (95% CI, 28.4 to 82.8)
  • SARS-CoV-2 S1 T-cell reactivity 3 weeks after second dose was highest in the participants with the heterologous vaccine regimen, compared to both other vaccine regimens
    • Heterologous
      • Median IFN-γ concentration 4762 mIU/mL (IQR 2723 to 8403)
    • Homologous Pfizer (P<0.0001)
      • Median IFN-γ concentration 1061 mIU/mL (IQR 599 to 2274)
    • Homologous AstraZeneca (P=0.0008)
      • Median IFN-γ concentration 2026 mIU/mL (IWR 1459 to 4621)

CONCLUSION:

  • Heterologous vaccine administration of AstraZeneca followed 10 to 12 weeks later with a dose of Pfizer, was as well tolerated as the homologous administration regimens and demonstrated improved immunogenicity vs homologous regimen of AstraZeneca or Pfizer
  • The authors conclude

In light of increasing occurrence of new virus variants carrying immune escape mutations, it will be important to determine vaccine efficacy of heterologous vaccination regimens, particularly regarding protection against severe COVID-19

Our data support further studies into the applicability of heterologous prime-boost vaccination strategies for COVID-19

Learn More – Primary Sources:

Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study

Get Mobile-Friendly COVID-19 Research Summaries with ObGFirst

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All COVID-19 Management Posts
Next >

Related ObG Topics:

AstraZeneca First Dose and mRNA Second Dose: How Does the ‘Mix & Match’ Immune Response Stack Up?
mRNA-Based COVID-19 Vaccines Induce Robust, Persistent Immune Responses in Humans
AstraZeneca and Pfizer Side Effects and Efficacy: Real World Data from the UK

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site